Current status of biological therapy use for older adults with severe asthma.

IF 3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2025-08-01 Epub Date: 2025-08-08 DOI:10.1080/17512433.2025.2546141

Alessandra Tomasello, Alida Benfante, Lorena Gentile, Giulia Genduso, Alessia Lombardino, Dario Macaluso, Nicola Scichilone

{"title":"Current status of biological therapy use for older adults with severe asthma.","authors":"Alessandra Tomasello, Alida Benfante, Lorena Gentile, Giulia Genduso, Alessia Lombardino, Dario Macaluso, Nicola Scichilone","doi":"10.1080/17512433.2025.2546141","DOIUrl":null,"url":null,"abstract":"Introduction: The management of severe asthma in older adults is an increasingly important clinical challenge. Aging-associated structural, functional, and immunological changes contribute to a distinct geriatric asthma phenotype, often marked by mixed inflammation, comorbidities, and reduced treatment responsiveness.Areas covered: This review provides an overview of current biologic therapies approved for severe asthma and examines existing clinical evidence regarding efficacy, safety, and real-world outcomes in geriatric patients. Clinical challenges include the heterogeneity of asthma phenotypes in this age group, and the impact of multimorbidity and polypharmacy on treatment outcomes.Expert opinion: A geriatric-centered approach to severe asthma is essential, emphasizing early initiation of biologic therapies, individualized risk-benefit analysis, and improved inclusion in research. The modulation of systemic inflammation, while carefully monitored, may bring also systemic benefits that may go beyond respiratory system. Achieving asthma remission in older adults is now a feasible goal, contingent upon proactive, tailored treatment strategies supported by more inclusive evidence.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"577-587"},"PeriodicalIF":3.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2025.2546141","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The management of severe asthma in older adults is an increasingly important clinical challenge. Aging-associated structural, functional, and immunological changes contribute to a distinct geriatric asthma phenotype, often marked by mixed inflammation, comorbidities, and reduced treatment responsiveness.

Areas covered: This review provides an overview of current biologic therapies approved for severe asthma and examines existing clinical evidence regarding efficacy, safety, and real-world outcomes in geriatric patients. Clinical challenges include the heterogeneity of asthma phenotypes in this age group, and the impact of multimorbidity and polypharmacy on treatment outcomes.

Expert opinion: A geriatric-centered approach to severe asthma is essential, emphasizing early initiation of biologic therapies, individualized risk-benefit analysis, and improved inclusion in research. The modulation of systemic inflammation, while carefully monitored, may bring also systemic benefits that may go beyond respiratory system. Achieving asthma remission in older adults is now a feasible goal, contingent upon proactive, tailored treatment strategies supported by more inclusive evidence.

查看原文本刊更多论文

老年严重哮喘患者生物治疗的现状

老年人严重哮喘的管理是一个日益重要的临床挑战。与衰老相关的结构、功能和免疫变化导致了一种独特的老年哮喘表型，通常以混合性炎症、合并症和治疗反应性降低为特征。涵盖领域：本综述概述了目前批准用于重度哮喘的生物疗法，并检查了有关老年患者的有效性、安全性和实际结果的现有临床证据。临床挑战包括该年龄组哮喘表型的异质性，以及多病和多药对治疗结果的影响。专家意见：以老年病学为中心的方法治疗严重哮喘至关重要，强调早期开始生物治疗，个体化风险-收益分析，并改善纳入研究。对全身炎症的调节，在仔细监测的同时，也可能带来全身的益处，可能超出呼吸系统。实现老年人哮喘缓解现在是一个可行的目标，这取决于有更多包容性证据支持的积极、量身定制的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.